The Scottish Medicines Consortium (SMC) has issued its monthly advice on newly licensed medicines.
Liraglutide (Saxenda®) has been rejected for use as an adjunct to a reduced-calorie diet and increased physical activity for weight management in adult patients with an initial Body Mass Index of:
- ≥30kg/m2 (obese)
- ≥27kg/m2 and <30kg/m2 (overweight) with at least one weight-related comorbidity such as dysglycaemia (pre-diabetes or type 2 diabetes mellitus), hypertension, dyslipidaemia or obstructive sleep apnoea
The manufacturer failed to make a submission.
Action: Clinicians should be aware of the recommendations of the SMC. Routine use of rejected and restricted medicines should be avoided.
|« CKS Updates - April 2017||NICE Guidance - May 2017 »|